A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, 3 + 3 dose escalation study to determine the safety and
preliminary efficacy of voruciclib in subjects with relapsed/refractory B cell malignancies
and AML after treatment with standard therapy.